Scientific deep-dive

Semaglutide for Alcohol Use Disorder: Read the Placebo Arm

Heavy drinking days fell 41.1 points on semaglutide and 26.4 points on placebo. The drug's effect is the 13.7-point difference, and it is real, significant and a third of the number that will be quoted.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·2 citations

A 2026 randomized trial gave weekly semaglutide or placebo to 108 people with both alcohol use disorder and obesity. Heavy drinking days fell by 41.1 percentage points in the semaglutide group. That figure is the one likely to be quoted, and it is the wrong one. The placebo group improved by 26.4 points, so the effect attributable to the drug is 13.7.[1]

The result, stated properly

Change in heavy drinking days from baseline, in percentage points. From the published report.
GroupChangeWhat it means
Semaglutide−41.1 (95% CI −48.7 to −33.5)The number that will be quoted
Placebo−26.4 (95% CI −34.1 to −18.6)The number that will not be
Treatment difference−13.7 (95% CI −22.0 to −5.4), p=0.0015The effect of the drug

The result is real. The confidence interval comfortably excludes zero, and the trial also reported substantial effects on multiple secondary alcohol-related and physical outcomes.[1] A 13.7 point reduction in heavy drinking days is a meaningful clinical effect in a condition where treatments are few and modest.

Why did placebo improve by 26 points? Because these were treatment-seeking people who enrolled in a trial, were assessed repeatedly, and knew their drinking was being measured. That is what wanting to change, plus structured attention, does, and it is a large part of what any addiction treatment delivers. It is also why a single-arm figure in this field is close to meaningless.

The same trap in another trial

The placebo arm also did much of the work behind the headline number in the fatty liver trial: steatohepatitis resolved in 62.9% on semaglutide and in 34.3% on placebo.

Where being watched helps, as with drinking, the drug’s contribution is a fraction of the raw change.

The pattern is not a quirk of these two studies. Any condition where being watched helps (drinking, eating, adherence, symptom scores) will produce a large placebo response, and the drug’s contribution will be a fraction of the raw change.

How far this generalizes

  • 108 participants, at a single center in Denmark. Small, and one health system.
  • Everyone had obesity as well as alcohol use disorder. Whether the effect holds in people with alcohol use disorder and a normal BMI is untested, and it matters, because weight loss itself may be part of the mechanism.
  • All were treatment-seeking. People who volunteer for an alcohol trial are not a random sample of people who drink heavily.
  • 81% completed the intervention, which is good for this field and still leaves a fifth unaccounted for.

The direction is consistent with a growing body of preclinical and clinical work suggesting GLP-1 receptors are involved in reward and craving, which we cover in GLP-1s and substance use. A small randomized trial in people who smoke (24 participants) missed both its primary endpoints,[2] so the effect may not be uniform across substances. For opioids there is no randomized trial yet, only records data on GLP-1s and opioid use disorder, which links a prescription to fewer overdoses.

What not to do with this

This is not a reason to obtain semaglutide from a telehealth seller to cut down on drinking. Alcohol use disorder is a condition where withdrawal can be life-threatening and where treatment involves far more than a prescription. No GLP-1 is approved for it anywhere. A trial result is a reason to talk to a clinician who treats addiction, not to go around one.

It is, though, an encouraging result in a field that badly needs them, and one to raise with a doctor if it describes your situation.

Frequently Asked Questions

In a randomized trial of 108 people with both alcohol use disorder and obesity, heavy drinking days fell 41.1 percentage points on semaglutide and 26.4 on placebo, a statistically significant treatment difference of 13.7 points. The drug's contribution is the 13.7, not the 41.
Because it was more than half the total improvement. Treatment-seeking people who enroll in a trial and have their drinking measured repeatedly improve substantially on their own. Quoting the 41-point figure alone overstates the drug's effect roughly threefold.
No. No GLP-1 is approved for alcohol use disorder anywhere. This is a single randomized trial of 108 people, and it is a reason for further research and for a conversation with a clinician, not a treatment pathway.
Untested. Everyone in the trial had obesity as well as alcohol use disorder, and weight loss may itself be part of how the effect works. Whether it holds at a normal BMI is an open question.
Not necessarily. A small randomized trial in people who smoke missed both its primary endpoints. The receptor biology involved in reward and craving is a live research area, but the results so far differ by substance.

References

  1. 1.Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial The Lancet. 2026. PMID: 42070571.
  2. 2.Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial JAMA Network Open. 2026. PMID: 42189538.

GLP-1 Drugs and Quitting Smoking: What the Trials Actually Tested

The largest randomized trial found a GLP-1 added nothing to quit rates (63% against 65% on placebo) while holding post-cessation weight for as long as it was taken. A year later that advantage had gone too.

7 min read

GLP-1 Drugs and Opioid Use Disorder: What the Records Data Shows

Across 503,747 people with opioid use disorder, a GLP-1 or GIP prescription carried an adjusted overdose rate ratio of 0.60. In methadone-treated patients it was associated with a higher rate of remission. No randomized trial exists.

6 min read

GLP-1 Drugs for PCOS: Eleven Trials, and Two Analyses That Disagree

No GLP-1 is approved for PCOS anywhere. The randomized evidence is eleven trials: a low-certainty weight effect, better insulin sensitivity than metformin, and reproductive outcomes two meta-analyses grade differently.

8 min read

GLP-1 Drugs and Eating Disorders: Two Questions, One Studied

Five studies covering 182 people make up the whole meta-analytic evidence base in binge eating disorder. What happens when these drugs reach someone with a restrictive eating disorder has never been studied at all.

6 min read

How Long Is the Evidence, Actually?

These are indefinite treatments. In the largest randomized trial at the weight indication, the mean time on the drug was 34.2 months. What the long trials ran for, and what a short evidence base does and does not mean.

7 min read

GLP-1 Drugs and Addiction: A Huge Signal, and a Trial That Missed

A 524,817-person cohort found fewer new substance use disorders of every kind measured. A randomized trial in people who smoke then missed both its primary endpoints. Both landed in 2026.

7 min read

Where to get semaglutide online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Luvo Health

Moving between compounded and brand without changing seller

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →